Your browser doesn't support javascript.
loading
Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014-2016.
Halenar, Michael J; Sargent, James D; Edwards, Kathryn C; Woloshin, Steven; Schwartz, Lisa; Emond, Jennifer; Tanski, Susanne; Pierce, John P; Taylor, Kristie A; Lauten, Kristin; Goniewicz, Maciej L; Niaura, Raymond; Anic, Gabriella; Chen, Yanling; Callahan-Lyon, Priscilla; Gardner, Lisa D; Thekkudan, Theresa; Borek, Nicolette; Kimmel, Heather L; Cummings, K Michael; Hyland, Andrew; Brunette, Mary F.
Afiliação
  • Halenar MJ; Westat, Rockville, MD 20850, USA.
  • Sargent JD; Geisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, NH 03755, USA.
  • Edwards KC; Westat, Rockville, MD 20850, USA.
  • Woloshin S; Dartmouth Institute for Health Policy and Clinical Practice, The C. Everett Koop Institute at Dartmouth, The Lisa Schwartz Foundation, Lebanon, NH 03766, USA.
  • Schwartz L; Dartmouth Institute for Health Policy and Clinical Practice, The C. Everett Koop Institute at Dartmouth, The Lisa Schwartz Foundation, Lebanon, NH 03766, USA.
  • Emond J; Geisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, NH 03755, USA.
  • Tanski S; Geisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, NH 03755, USA.
  • Pierce JP; Moores Cancer Center, University of California at San Diego, La Jolla, CA 92037, USA.
  • Taylor KA; Westat, Rockville, MD 20850, USA.
  • Lauten K; Westat, Rockville, MD 20850, USA.
  • Goniewicz ML; Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
  • Niaura R; School of Global Public Health, New York University, New York, NY 10012, USA.
  • Anic G; Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Chen Y; Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Callahan-Lyon P; Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Gardner LD; Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Thekkudan T; Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Borek N; Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Kimmel HL; National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20852, USA.
  • Cummings KM; Department of Psychiatry & Behavioral Science, Medical University of South Carolina, Mt. Pleasant, SC 29464, USA.
  • Hyland A; Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
  • Brunette MF; Geisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, NH 03755, USA.
Article em En | MEDLINE | ID: mdl-34574610
ABSTRACT
The purpose of this study is to validate the seven-item wheezing module from the International Study of Asthma and Allergies in Children (ISAAC) in the nationally representative Population Assessment of Tobacco and Health Study. Adult participants with complete Wave 2-3 data were selected, including those with asthma but excluding those with COPD and other respiratory diseases (n = 16,295). We created a nine-point respiratory symptom index from the ISAAC questions, assessed the reliability of the index, and examined associations with self-reported asthma diagnosis. Threshold values were assessed for association with functional outcomes. The weighted prevalence for one or more respiratory symptom was 18.0% (SE = 0.5) for adults without asthma, 70.1% (SE = 1.3) for those with lifetime asthma, 75.7% (SE = 3.7) for adults with past-year asthma not on medications, and 92.6% (SE = 1.6) for those on medications. Cronbach's alpha for the respiratory symptom index was 0.86. Index scores of ≥2 or ≥3 yielded functionally important respiratory symptom prevalence of 7-10%, adequate sensitivity and specificity for identifying asthma, and consistent independent associations with all functional outcomes and tobacco use variables. Respiratory symptom index scores of ≥2 or ≥3 are indicative of functionally important respiratory symptoms and could be used to assess the relationship between tobacco use and respiratory health.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Nicotiana Tipo de estudo: Diagnostic_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Nicotiana Tipo de estudo: Diagnostic_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article